75% decreased risk of treatment failure compared to MTX alone.
*HUMIRA® (adalimumab) is approved for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and children 2 years of age and older.
Reasons to consider HUMIRA as an option in treating non-infectious uveitis*
HUMIRA is the first and only FDA-approved biologic proven to treat non-infectious intermediate, posterior, and panuveitis in adults and children 2 years of age and older.
HUMIRA is a whole different way to treat non-infectious uveitis.* It is not a steroid.
HUMIRA targets and blocks a specific source of inflammation that plays a role in
non-infectious uveitis.*
When to consider HUMIRA as a treatment option
Your doctor may prescribe HUMIRA if:
- you are not responding to or can’t tolerate other treatments.
- steroid treatments are not working.
- you’ve been on moderate or high doses of corticosteroids for more than 1 month.
HUMIRA increased the time non-infectious uveitis* was controlled
In a study of adult patients with active, non-infectious intermediate, posterior, and panuveitis, disease control was defined by 4 combined measurements—the first 3 contribute to what’s commonly known as a flare:
Vitreous haze (cloudiness in the middle of the eye).
Inflammatory cells in the front of the eye.
New lesions on the back of the eye.
Maintenance of visual clarity (ability to read an eye chart at a distance).
In the same clinical study of adult patients with active disease
HUMIRA patients experienced 50% decreased risk of a combination of flare and loss of visual clarity.
Differences in disease control were seen as early as 6 weeks for patients taking HUMIRA.
Treating non-infectious uveitis* in children 2 and older
In a clinical study of children 2 years of age and older with non-infectious uveitis* who had been previously diagnosed with Juvenile Idiopathic Arthritis (JIA), HUMIRA in combination with another drug called methotrexate (MTX) was proven to increase the time non-infectious uveitis* was controlled.
HUMIRA is not a steroid, and can reduce topical steroid use in children 2 and older with
non-infectious uveitis.*
After some time using HUMIRA, I started seeing improvement. My disease was being controlled.
-Joanne B., non-infectious intermediate uveitis patient
Prescribed to treat inflammatory conditions for over 15 years
HUMIRA was approved to treat non-infectious uveitis* fairly recently. But it was first approved to treat an inflammatory condition over 15 years ago and, over time, has been approved to treat a total of 10 inflammatory diseases, including 3 pediatric conditions.
*HUMIRA (adalimumab) is approved for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and children 2 years of age and older.
Helpful Links
Has your child been prescribed HUMIRA?
What to ExpectUS-HUMU-190024
